Gatekeepers for pragmatic clinical trials
- 15 September 2015
- journal article
- research article
- Published by SAGE Publications in Clinical Trials
- Vol. 12 (5), 442-448
- https://doi.org/10.1177/1740774515597699
Abstract
To successfully implement a pragmatic clinical trial, investigators need access to numerous resources, including financial support, institutional infrastructure (e.g. clinics, facilities, staff), eligible patients, and patient data. Gatekeepers are people or entities who have the ability to allow or deny access to the resources required to support the conduct of clinical research. Based on this definition, gatekeepers relevant to the US clinical research enterprise include research sponsors, regulatory agencies, payers, health system and other organizational leadership, research team leadership, human research protections programs, advocacy and community groups, and clinicians. This article provides a framework to help guide gatekeepers’ decision-making related to the use of resources for pragmatic clinical trials. Relevant ethical considerations for gatekeepers include (1) concern for the interests of individuals, groups, and communities affected by the gatekeepers’ decisions, including protection from harm and maximization of benefits; (2) advancement of organizational mission and values; and (3) stewardship of financial, human, and other organizational resources. Separate from these ethical considerations, gatekeepers’ actions will be guided by relevant federal, state, and local regulations. This framework also suggests that to further enhance the legitimacy of their decision-making, gatekeepers should adopt transparent processes that engage relevant stakeholders when feasible and appropriate. We apply this framework to the set of gatekeepers responsible for making decisions about resources necessary for pragmatic clinical trials in the United States, describing the relevance of the criteria in different situations and pointing out where conflicts among the criteria and relevant regulations may affect decision-making. Recognition of the complex set of considerations that should inform decision-making will guide gatekeepers in making justifiable choices regarding the use of limited and valuable resources.Keywords
This publication has 24 references indexed in Scilit:
- The Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized TrialsPLoS Medicine, 2012
- What is the role and authority of gatekeepers in cluster randomized trials in health research?Trials, 2012
- The Multiple Myeloma Research Foundation's evolving focus on drug R&DNature Biotechnology, 2012
- The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness researchClinical Trials, 2012
- Improving the recruitment activity of clinicians in randomised controlled trials: a systematic reviewBMJ Open, 2012
- Successful recruitment to trials: a phased approach to opening gates and building bridgesBMC Medical Research Methodology, 2011
- Ethical issues posed by cluster randomized trials in health researchTrials, 2011
- Generating Evidence for Comparative Effectiveness Research Using More Pragmatic Randomized Controlled TrialsPharmacoEconomics, 2010
- A survey of the views of palliative care healthcare professionals towards referring cancer patients to participate in randomized controlled trials in palliative careSupportive Care in Cancer, 2008
- Deliberating about BioethicsMaterials, 1997